Literature DB >> 35610079

CircSLC8A1 targets miR-181a-5p/HIF1AN pathway to inhibit the growth, migration and extracellular matrix deposition of human keloid fibroblasts.

Xiaoye Yuan1, Baiye Chen2, Xueming Wang3.   

Abstract

BACKGROUND: Circular RNAs (circRNAs) are identified as important regulators in human diseases, including keloid. The purpose of this study is to reveal the role and molecular mechanism of circSLC8A1 in keloid formation.
METHODS: Expression of circSLC8A1, microRNA (miR)-181a-5p, and hypoxia inducible factor 1 alpha inhibitor (HIF1AN) were detected by quantitative real-time PCR. Protein expression of extracellular matrix (ECM) deposition markers and HIF1AN was detected by western blot analysis. Furthermore, the interaction between miR-181a-5p and circSLC8A1 or HIF1AN was confirmed by dual-luciferase reporter assay, RIP assay and RNA pull-down assay.
RESULTS: Expression of circSLC8A1 was downregulated in keloid tissues and HKFs. Overexpression of circSLC8A1 suppressed HKFs proliferation, migration, ECM deposition, and promoted apoptosis. MiR-181a-5p is targeted by circSLC8A1, and its mimic reversed the effect of circSLC8A1 on the biological function of HKFs. HIF1AN was a target of miR-181a-5p, and it was positively regulated by circSLC8A1. Knockdown of HIF1AN also reversed the negatively regulation of circSLC8A1 on the biological functions of HKFs.
CONCLUSION: Our data showed that circSLC8A1 regulates the miR-181a-5p/HIF1AN axis to restrain HKFs biological functions, confirming that circSLC8A1 might serve as a novel therapeutic target for keloids.
Copyright © 2022 Elsevier Ltd and International Society of Burns Injuries. All rights reserved.

Entities:  

Keywords:  CircSLC8A1; HIF1AN; Human keloid fibroblasts; Keloid; MiR-181a-5p

Year:  2022        PMID: 35610079     DOI: 10.1016/j.burns.2022.04.009

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  1 in total

Review 1.  Emerging roles of long non-coding RNAs in keloids.

Authors:  Xin Yu; Xueqing Zhu; Hongjun Xu; Linfeng Li
Journal:  Front Cell Dev Biol       Date:  2022-08-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.